KVP Capital Advisors, LP — 13F Holdings & Portfolio
CIK 1858198 · latest 13F-HR filed 2026-08-13
KVP Capital Advisors, LP manages $136.2M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PRAX (10.54%), WHWK (7.28%), ERAS (6.12%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions and exited 3; 18 existing positions rose in reported value and 7 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-13
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q2 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q1 26 → Q2 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
3 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 57.4%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Jun 29, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CASTELEIN, CALEY, MCNEILL Control | MANAGING DIRECTOR / LIMITED PARTNER since Nov 2014 | 75% or more | Individual |
| CASTELEIN, CALEY, MCNEILL Control | MANAGING DIRECTOR / LIMITED PARTNER since Nov 2014 | 75% or more | Individual |
| JENSEN, ANDREW, IRVING Control | CHIEF FINANCIAL OFFICER since Nov 2014 | 10–25% | Individual |
| JENSEN, ANDREW, IRVING Control | CHIEF FINANCIAL OFFICER since Nov 2014 | 10–25% | Individual |
| KVP CAPITAL ADVISORS, LLC Control | GENERAL PARTNER since Nov 2014 | Less than 5% | Domestic Entity |
| KVP CAPITAL ADVISORS, LLC Control | GENERAL PARTNER since Nov 2014 | Less than 5% | Domestic Entity |
| GUARINO, PETER, ROSERIO | CHIEF COMPLIANCE OFFICER since Jun 2026 | Less than 5% | Individual |
| GUARINO, PETER, ROSERIO | CHIEF COMPLIANCE OFFICER since Jun 2026 | Less than 5% | Individual |
| CASTELEIN, CALEY, MCNEILL Control Indirect owner via KVP CAPITAL ADVISORS, LLC | OWNER since Nov 2014 | 75% or more | Individual |
| CASTELEIN, CALEY, MCNEILL Control Indirect owner via KVP CAPITAL ADVISORS, LLC | OWNER since Nov 2014 | 75% or more | Individual |
Ownership & leadership changes · 9 filings with changes since Jan 2, 2015
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedGUARINO, PETER, ROSERIO · CHIEF COMPLIANCE OFFICER · Less than 5%
- ChangedCASTELEIN, CALEY, MCNEILL · title MANAGING DIRECTOR / LIMITED PARTNER → LIMITED PARTNER / MANAGING DIRECTOR / MANAGING DIRECTOR / LIMITED PARTNER
- ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER/ CHIEF COMPLIANCE OFFICER → CHIEF FINANCIAL OFFICER
- ChangedJENSEN, ANDREW, IRVING · ownership 5–10% → 10–25%
- ChangedCASTELEIN, CALEY, MCNEILL · title LIMITED PARTNER / MANAGING DIRECTOR / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → MANAGING DIRECTOR / LIMITED PARTNER
- ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → CHIEF FINANCIAL OFFICER/ CHIEF COMPLIANCE OFFICER
- No longer listedDALAL, ANUPAM, AKSHAY · MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) · 10–25% · control person · listed since Nov 2014
- ChangedCASTELEIN, CALEY, MCNEILL · title LIMITED PARTNER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → LIMITED PARTNER / MANAGING DIRECTOR / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
- ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → CHIEF FINANCIAL OFFICER / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
- ChangedKVP CAPITAL ADVISORS, LLC · title GENERAL PARTNER (KVP CAPITAL ADVISORS, LP) → GENERAL PARTNER
- ChangedCASTELEIN, CALEY, MCNEILL · indirect via KVP CAPITAL ADVISORS, LLC: ownership 25–50% → 75% or more
- No longer listedDALAL, ANUPAM, AKSHAY · OWNER · 25–50% · indirect via KVP CAPITAL ADVISORS, LLC · control person · listed since Nov 2014
- ChangedCASTELEIN, CALEY, MCNEILL · ownership 25–50% → 75% or more
- ChangedDALAL, ANUPAM, AKSHAY · title LIMITED PARTNER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC); ownership 25–50% → 10–25%
- ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → CHIEF FINANCIAL OFFICER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
- ChangedCASTELEIN, CALEY, MCNEILL · title LIMITED PARTNER → LIMITED PARTNER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
- ChangedDALAL, ANUPAM, AKSHAY · title LIMITED PARTNER → LIMITED PARTNER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
- ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC); ownership Less than 5% → 5–10%
- ChangedKVP CAPITAL ADVISORS, LLC · title GENERAL PARTNER → GENERAL PARTNER (KVP CAPITAL ADVISORS, LP)
- ListedCASTELEIN, CALEY, MCNEILL · LIMITED PARTNER · 25–50% · control person
- ListedCASTELEIN, CALEY, MCNEILL · OWNER · 25–50% · indirect via KVP CAPITAL ADVISORS, LLC · control person
- ListedDALAL, ANUPAM, AKSHAY · LIMITED PARTNER · 25–50% · control person
- ListedDALAL, ANUPAM, AKSHAY · OWNER · 25–50% · indirect via KVP CAPITAL ADVISORS, LLC · control person
- ListedJENSEN, ANDREW, IRVING · CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedKVP CAPITAL ADVISORS, LLC · GENERAL PARTNER · Less than 5% · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- MBX BIOSCIENCES INC$3.1M +84.9%
- ERASCA INC$2.8M +51.5%
- TREVI THERAPEUTICS INC$2.8M +56.3%
- WHITEHAWK THERAPEUTICS INC$2.4M +32.8%
- TANGO THERAPEUTICS INC$2.4M +49.4%
Top Trims
- AXSOME THERAPEUTICS INC.-$3.2M -52.0%
- INSMED INC-$1.6M -34.8%
- COMPASS THERAPEUTICS INC-$956.5K -36.2%
- TRAVERE THERAPEUTICS INC-$488.0K -18.1%
- UNITED THERAPEUTICS CORP DEL-$243.0K -8.6%
New Positions
- TANDEM DIABETES CARE INC$4.5M
- ARRIVENT BIOPHARMA INC$3.5M
- DESIGN THERAPEUTICS INC$2.7M
- MINERALYS THERAPEUTICS INC$2.3M
- ARTIVA BIOTHERAPEUTICS INC$1.9M
Exited Positions
Show all 3 →KVP Capital Advisors, LP Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $14.4M | 10.54% | 42,900 | SH |
| 2 | WHITEHAWK THERAPEUTICS INC | WHWK | 00032Q104 | $9.9M | 7.28% | 2,165,997 | SH |
| 3 | ERASCA INC | ERAS | 29479A108 | $8.3M | 6.12% | 455,000 | SH |
| 4 | TREVI THERAPEUTICS INC | TRVI | 89532M101 | $7.7M | 5.67% | 414,000 | SH |
| 5 | SUTRO BIOPHARMA INC | STRO | 869367201 | $7.5M | 5.52% | 226,575 | SH |
| 6 | TANGO THERAPEUTICS INC | TNGX | 87583X109 | $7.2M | 5.28% | 230,264 | SH |
| 7 | MBX BIOSCIENCES INC | MBX | 55287L101 | $6.7M | 4.92% | 121,524 | SH |
| 8 | PROTAGONIST THERAPEUTICS INC | PTGX | 74366E102 | $6.5M | 4.77% | 53,000 | SH |
| 9 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $5.4M | 3.97% | 133,000 | SH |
| 10 | TANDEM DIABETES CARE INC | TNDM | 875372203 | $4.5M | 3.33% | 301,000 | SH |
| 11 | DISC MEDICINE INC | IRON | 254604101 | $4.3M | 3.13% | 58,250 | SH |
| 12 | SAVARA INC | SVRA | 805111101 | $3.7M | 2.74% | 605,280 | SH |
| 13 | ARRIVENT BIOPHARMA INC | AVBP | 04272N102 | $3.5M | 2.60% | 102,000 | SH |
| 14 | INSMED INC | INSM | 457669307 | $3.0M | 2.23% | 28,497 | SH |
| 15 | ACHIEVE LIFE SCIENCES INC | QUIT | 004468500 | $3.0M | 2.22% | 462,355 | SH |
| 16 | IDEAYA BIOSCIENCES INC | IDYA | 45166A102 | $3.0M | 2.18% | 79,700 | SH |
| 17 | OCULAR THERAPEUTIX INC | OCUL | 67576A100 | $2.9M | 2.16% | 300,000 | SH |
| 18 | AXSOME THERAPEUTICS INC. | AXSM | 05464T104 | $2.9M | 2.16% | 12,000 | SH |
| 19 | DESIGN THERAPEUTICS INC | DSGN | 25056L103 | $2.7M | 1.96% | 185,000 | SH |
| 20 | UNITED THERAPEUTICS CORP DEL | UTHR | 91307C102 | $2.6M | 1.89% | 4,750 | SH |
| 21 | SCHOLAR ROCK HLDG CORP | SRRK | 80706P103 | $2.5M | 1.82% | 45,000 | SH |
| 22 | IMMIX BIOPHARMA INC | IMMX | 45258H106 | $2.4M | 1.74% | 230,423 | SH |
| 23 | VIRIDIAN THERAPEUTICS INC | VRDN | 92790C104 | $2.3M | 1.69% | 125,000 | SH |
| 24 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $2.3M | 1.67% | 84,168 | SH |
| 25 | BRIGHT MINDS BIOSCIENCES INC | DRUG | 10919W405 | $2.2M | 1.64% | 31,813 | SH |
| 26 | TRAVERE THERAPEUTICS INC | TVTX | 89422G107 | $2.2M | 1.63% | 39,000 | SH |
| 27 | ZURA BIO LTD | ZURA | G9TY5A101 | $2.2M | 1.62% | 373,128 | SH |
| 28 | ARTIVA BIOTHERAPEUTICS INC | ARTV | 04317A107 | $1.9M | 1.42% | 200,000 | SH |
| 29 | NEKTAR THERAPEUTICS | NKTR | 640268306 | $1.9M | 1.38% | 26,900 | SH |
| 30 | COMPASS THERAPEUTICS INC | CMPX | 20454B104 | $1.7M | 1.24% | 771,000 | SH |
| 31 | CABALETTA BIO INC | CABA | 12674W109 | $1.6M | 1.15% | 505,431 | SH |
| 32 | VERA THERAPEUTICS INC | VERA | 92337R101 | $1.4M | 1.03% | 32,700 | SH |
| 33 | EVOLUS INC | EOLS | 30052C107 | $1.0M | 0.76% | 150,000 | SH |
| 34 | CELCUITY INC | CELC | 15102K100 | $418.5K | 0.31% | 4,000 | SH |
| 35 | VYNE THERAPEUTICS INC | VYNE | 92941V308 | $325.7K | 0.24% | 500,551 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-13 | $136.2M | 35 | 0001104659-26-095988 |
| 2026-03-31 | 2026-05-13 | $133.9M | 32 | 0001104659-26-060329 |
| 2025-12-31 | 2026-02-18 | $103.3M | 27 | 0001104659-26-016901 |
SUITE 2100
SAN FRANCISCO, CA 94111